Literature DB >> 8424398

The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study.

J R Skillings1, F G Sridhar, C Wong, L Paddock.   

Abstract

The objective of this retrospective cohort study was to determine the frequency of red cell transfusion for anemia and risk factors. It was conducted at a regional cancer center and host hospital. All patients receiving chemotherapy in 1989 were studied. Complete data were available on 381; 26 were excluded. Age, diagnosis, baseline and nadir hemoglobin, transfusion history, chemotherapy regimen, and prior treatment were abstracted from the cancer center chart and hospital medical records. Transfusion for anemia was required in 18% of all patients with solid tumors; those with lung cancer had the highest rate (34%). Patients with anemia who entered chemotherapy were more likely to be transfused. Therefore, patients with leukemia, lung cancer, and/or prior anemia have higher transfusion rates and may benefit from such therapies as recombinant human erythropoietin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8424398     DOI: 10.1097/00000421-199302000-00006

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  14 in total

1.  Recombinant human erythropoietin (rhEPO) in the prevention and treatment of chemotherapy-induced anaemia.

Authors:  M R Nowrousian
Journal:  Med Oncol       Date:  1998-09       Impact factor: 3.064

2.  The impact of hemoglobin level and transfusion on the outcomes of chemotherapy in gastric cancer patients.

Authors:  Xianren Ye; Jingfu Liu; Yujuan Chen; Na Wang; Rong Lu
Journal:  Int J Clin Exp Med       Date:  2015-03-15

3.  Ratio of baseline erythropoietin (EPO) level and corrected reticulocyte count as an indicator for a favourable response to recombinant human erythropoietin (rhEPO) therapy in anaemic cancer patients.

Authors:  N Charuruks; N Voravud; W Limpanasithikul
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

Review 4.  Clinical and economic impact of epoetins in cancer care.

Authors:  Monia Marchetti; Giovanni Barosi
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 5.  The clinical value of erythropoietin in patients with cancer.

Authors:  Ulrich Dührsen
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 6.  A risk-benefit assessment of epoetin in the management of anaemia associated with cancer.

Authors:  Y Beguin
Journal:  Drug Saf       Date:  1998-10       Impact factor: 5.606

Review 7.  Hematopoietic growth factors and the treatment of tumor-associated anemias.

Authors:  U Dührsen; D K Hossfeld
Journal:  Ann Hematol       Date:  1994-11       Impact factor: 3.673

8.  Lifetime Transfusion Burden and Transfusion-Related Iron Overload in Adult Survivors of Solid Malignancies.

Authors:  F J Sherida H Woei-A-Jin; Shu Zhen Zheng; Inci Kiliçsoy; Francisca Hudig; Saskia A C Luelmo; Judith R Kroep; Hildo J Lamb; Susanne Osanto
Journal:  Oncologist       Date:  2019-08-27

9.  Effects of funding policy changes and health warnings on the use of erythropoiesis-stimulating agents.

Authors:  Matthew A Weir; Tara Gomes; Eric Winquist; David N Juurlink; Meaghan S Cuerden; Muhammad Mamdani
Journal:  J Oncol Pract       Date:  2012-01-17       Impact factor: 3.840

10.  Predictors and patterns of red blood cell transfusion use among newly diagnosed cancer patients with chemotherapy-associated anemia in Western Denmark (1998-2003).

Authors:  Mellissa Yong; Anders H Riis; Jon P Fryzek; Bjarne K Møller; Søren P Johnsen
Journal:  Clin Epidemiol       Date:  2011-03-01       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.